SG Americas Securities
AEGR

SG Americas Securities’s Aegerion Pharmaceuticals AEGR Stock Holding History

SG Americas Securities’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-35,831
Closed -$133K – 3246
2016
Q1 		$133K Buy
+35,831
New +$222K ﹤0.01% 2453
2015
Q1 		– Sell
-14,108
Closed -$295K – 3334
2014
Q4 		$295K Sell
14,108
-51,676
-79% -$1.3M ﹤0.01% 2088
2014
Q3 		$2.2M Buy
65,784
+61,947
+1,614% +$1.92M 0.01% 848
2014
Q2 		$123K Sell
3,837
-9,017
-70% -$336K ﹤0.01% 2263
2014
Q1 		$593K Buy
+12,854
New +$754K ﹤0.01% 1379
2013
Q4 		– Sell
-5,843
Closed -$501K – 3266
2013
Q3 		$501K Buy
5,843
+266
+5% +$22.5K ﹤0.01% 1610
2013
Q2 		$353K Buy
+5,577
New +$296K ﹤0.01% 1425

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SG Americas Securities's AEGR Position: Q2 2016 in Review

SG Americas Securities sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 35,831 shares — an estimated $133K sold.

SG Americas Securities first reported a position in AEGR in Q2 2013 and held it in 7 quarters. The position peaked at $2.2M in Q3 2014. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • SG Americas Securities reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • SG Americas Securities sold 35,831 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $133K.
  • SG Americas Securities first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • SG Americas Securities's Aegerion Pharmaceuticals position peaked at $2.2M in Q3 2014.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on SG Americas Securities's 13F filing for Q2 2016, filed 3 Aug 2016.